The Italian Olon Group, a leading international supplier of active pharmaceutical ingredients (APIs), presents the 2023 Corporate Sustainability Report and confirms the sustainability journey toward energy transition, investments in alternative energy sources, social and economic involvement and support for the communities in which it operates
Olon continues its growth path and increases its total production capacity following the acquisition of Huvepharma Italia and its site in Garessio, Cuneo, in the northwestern part of Italy.
US biotech company Antheia and Olon, an Italian producer of active pharmaceutical ingredients (APIs), have announced the continuation of their ongoing partnership to utilize Olon’s fermentation infrastructure for the scale-up and commercialization of Antheia’s early products.
Olon Group is building a state-of-the-art High Potency Active Pharmaceutical Ingredient (HPAPI) suite at its Olon USA site in Concord, Ohio. This expands the company's capabilities for handling HPAPI, with investments totaling around €40 million ($43 million) in recent years.
Olon, an Italian CDMO and API producer of active pharmaceutical ingredients (APIs), plans to invest €10 million in a multi-year expansion of its production site in Mahad, India.
Olon Biotech, a division of Italian API producer Olon, has inaugurated a new facility for the industrial-scale production of proteins from alternative sources at its site in Settimo, Italy. Olon pegged the investment in the new plant at €70 million.
Maurizio Sartorato has joined international API supplier Olon as Vice President of the group's Biotech division. In his new role, he will be a member of Olon’s leadership team.
Italian API producer Olon has started building a second facility at its Rodano site in Milan that will be entirely dedicated to producing ultra-potent compounds.
Olon, an Italian CDMO and API producer, is investing a total of €100 million in 2023 to increase production capacity, in particular at its site in Mulazzano, Lodi province.
Italian API producer Olon has announced plans to install a new high-containment production line at its site in Mahad, India.
Major API supplier Olon is establishing a €10 million central R&D hub at its headquarters site in Roadano, near Milan. The Italian company said the facility paves the way for a further major expansion and diversification of its expertise in active pharmaceutical ingredients supplied to the CDMO and generics markets.
With this acquisition, Olon said it has successfully finalized its three-year development plan and will now move to its next target, which is to play an important role in manufacturing biologics APIs.
Growth in the global oncology drug market is an important measure of opportunities in drug development and manufacturing, including for contract manufacturers of active pharmaceutical ingredients (APIs) and finished drug products.
